KCNJ5 and metabolic disease: In the TAIPAI group, Chen et al20 evaluated the prevalence of metabolic disorders and abdominal obesity, showing that patients with uPA who harbored KCNJ5 mutations had a significantly lower prevalence of metabolic syndrome and a lower distribution of body adipose tissue.